| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.12B | -0.8% |
| Gross profit | ¥0.06B | — |
| Operating income | ¥-0.02B | — |
| Net income | ¥-0.02B | -237.3% |
| Gross margin | 53.0% | Net margin -15.4% |
| Revenue Q/Q | -20.5% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.06B | 47.0% |
| R&D | ¥0.03B | 24.5% |
| SG&A | ¥0.03B | 25.4% |
| Tax & other | ¥-0.00B | -1.8% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
新美星 ・ 金冠股份 ・ 雪榕生物 ・ 中亚股份 ・ 恒实科技 ・ 友讯达 ・ 三德科技 ・ 久之洋 ・ 海波重科 ・ 新迅达 ・ 新光药业 ・ 科大国创
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies